Tuesday, August 3, 2010

Generic Aricept Teva Pharmaceuticals USA Responds to Us


By Bob DeMarco
Alzheimer's Reading Room

Teva Pharmaceuticals was in a long drawn out patent litigation with Eisai over the rights to manufacture and distribute a generic version of Aricept. The original litigation dates back to 2005. The litigation finally ended last month.

Generics maker Teva Pharmaceuticals USA Inc. has agreed to suspend litigation over a compound patent for Eisai Co. Ltd.'s popular Alzheimer's drug Aricept, effectively ending Teva's bid to manufacture a generic version of the drug before the patent expires in November.


It seems to me that Teva is going to hit the market with generic Aricept on the first day possible. Right now, we know the patent expires in November.

I decided to email Teva Pharmaceuticals USA and see if there was any information available.

This is the response I received via email.

This email is in response to your request for information about Donepezil Hydrochloride Tablets. You asked when this product would be available.

Teva USA can make no comment on any product not yet marketed in the U.S. Thank you for your interest in Teva Pharmaceuticals USA.

Fair enough, this is where we are right now.

More news and information to follow as soon as it is available.

Also see:

Generic Aricept -- Patent Due To Expire on November 25, 2010


Generic Aricept and Namenda Update




Subscribe to the Alzheimer's Reading Room

Enter Your Email Address


More About the Alzheimer's Reading Room



The Alzheimer's Action Plan
 
300 Tips for Making Life Easier

Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. Bob has written more than 1,690 articles with more than 70,000 links on the Internet. Bob resides in Delray Beach, FL.

Original content Bob DeMarco, the Alzheimer's Reading Room